News & Updates

Localized administration of colistin reduces the incidence of systemic adverse events in patients with lower respiratory tract infection (LRTI), a recent study has shown.

A marginal decrease in forced vital capacity (FVC) ≥5 percent and diffusion capacity of the lung for carbon monoxide (DLCO) ≥10 percent appears to raise the risk of mortality in patients with fibrotic hypersensitivity pneumonitis (fHP), suggests a study.

Real-world interim findings from the phase IV, noninterventional EMPOWER trial showed reduced attack rates and improved quality of life (QoL) in individuals who received lanadelumab for the treatment of hereditary angioedema (HAE).

For type 2 diabetes patients (T2D), the presence of any fracture contributes to a significant increase in the risk of mortality, a study has found.

An intervention that involves informational and reminder text messages, among others, is a feasible approach for managing elevated blood pressure (BP) in the emergency department (ED) setting, as reported in a study.

Adding darolutamide to androgen-deprivation therapy (ADT) plus docetaxel significantly increases overall survival (OS) in patients with metastatic, hormone-sensitive prostate cancer (mHSPC), according to the ARASENS* trial presented at the ASCO GUCS 2022.